Axon Enterprise’s (AXON) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Axon Enterprise (NASDAQ:AXON) in a report issued on Wednesday morning,Benzinga reports. They currently have a $600.00 price objective on the biotechnology company’s stock.

A number of other analysts also recently issued reports on AXON. JMP Securities reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Northland Securities raised their price objective on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. TD Cowen began coverage on Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price objective for the company. Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Finally, Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “hold” rating and set a $625.00 price objective for the company. in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $587.38.

Axon Enterprise Stock Up 0.6 %

Shares of NASDAQ:AXON opened at $528.45 on Wednesday. The business has a 50-day moving average price of $609.55 and a 200 day moving average price of $523.20. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $40.30 billion, a price-to-earnings ratio of 136.55, a PEG ratio of 5.17 and a beta of 1.05. Axon Enterprise has a 12-month low of $273.52 and a 12-month high of $715.99.

Insider Transactions at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the transaction, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 1,261 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total value of $860,077.66. Following the transaction, the director now directly owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. This represents a 34.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,711 shares of company stock valued at $5,631,561. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently made changes to their positions in AXON. Public Sector Pension Investment Board lifted its stake in Axon Enterprise by 19.2% during the third quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock worth $1,240,000 after purchasing an additional 500 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Axon Enterprise by 9.2% during the third quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after purchasing an additional 895 shares during the last quarter. Axxcess Wealth Management LLC purchased a new stake in Axon Enterprise during the third quarter worth approximately $814,000. Soros Capital Management LLC purchased a new stake in Axon Enterprise during the third quarter worth approximately $630,000. Finally, Friedenthal Financial lifted its stake in Axon Enterprise by 961.7% during the fourth quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock worth $808,000 after purchasing an additional 1,231 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.